- Home
- GRRR vs FBRX Comparison
GRRR vs FBRX Comparison
Compare GRRR & FBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GRRR | FBRX |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 323.0M | 379.3M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | GRRR | FBRX |
|---|---|---|
| Price | $10.52 | $27.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $67.00 |
| AVG Volume (30 Days) | ★ 513.1K | 190.3K |
| Earning Date | 03-02-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $69.35 | N/A |
| Revenue Next Year | $85.38 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $10.30 | $4.91 |
| 52 Week High | $29.71 | $35.62 |
Technical Indicators
Market Signals| Indicator | GRRR | FBRX |
|---|---|---|
| Relative Strength Index (RSI) | 41.88 | 49.29 |
| Support Level | N/A | $26.67 |
| Resistance Level | $13.39 | $32.40 |
| Average True Range (ATR) | 0.54 | 2.34 |
| MACD | -0.04 | -0.03 |
| Stochastic Oscillator | 12.37 | 61.35 |
Price Performance
Historical ComparisonAbout GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About FBRX Forte Biosciences Inc.
Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).